In this article, we are going to take a look at where Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) stands against other worst high-risk high-reward growth stocks to buy. On March 14 ...

Arcturus Therapeutics Holdings Inc is a biotechnology firm based in San Diego, California, specializing in the development of innovative mRNA medicines and vaccines. With a focus on addressing ...

Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Free ...

Arcturus Therapeutics (ARCT) had a challenging fourth quarter, with revenue and earnings falling short of analyst expectations. Their annual revenue took a dip, dropping $14.5 million from the ...

Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) is set to release its Q4 2024 earnings on Mar 6, 2025.The consensus estimate for Q4 2024 revenue is $44.65 million, and the earnings are expected ...

Canaccord analyst Whitney Ijem lowered the firm’s price target on Arcturus Therapeutics (ARCT) to $68 from $74 and keeps a Buy rating on the shares. The firm said its 4Q24 earnings report had ...

SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...